Sarah Kiely
Contatto Relazioni con gli Investitori presso PROQR THERAPEUTICS N.V.
Profilo
Sarah Kiely is currently the VP-Investor Relations & Corporate Affairs at ProQR Therapeutics NV.
Prior to her current position, she worked as the Director-Investor Relations & Communications at ImmunoGen, Inc. from 2012 to 2019.
Ms. Kiely holds an MBA from Boston University and an undergraduate degree from Boston College.
Posizioni attive di Sarah Kiely
| Società | Posizione | Inizio |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Contatto Relazioni con gli Investitori | 01/10/2019 |
Precedenti posizioni note di Sarah Kiely
| Società | Posizione | Fine |
|---|---|---|
| IMMUNOGEN, INC. | Contatto Relazioni con gli Investitori | 01/07/2019 |
Formazione di Sarah Kiely
| Boston University | Masters Business Admin |
| Boston College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PROQR THERAPEUTICS N.V. | Health Technology |
| Aziende private | 1 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- Sarah Kiely
